PMC4950584_01
The development of hematological parameters and the JAK2-V617F allele burden and an overview of the treatment.
gr1.jpg
PMC4950584_01_gr1.jpg
f0005
Fig. 1 illustrates the treatment and responses in hematological parameters along with the JAK2-V617F allele burden. During these 56 months, after initiation of alendronate, the patient was largely in complete hematological remission (the platelet count was temporarily above 400x109/L on some occasions) without need for further phlebotomies, and the JAK2-V617F mutation status 44 months after PV-diagnosis revealed a marked decrease in the allele burden from 64.0% to 21.4% (Fig. 1).
Bone marrow biopsies from 2008, 2013 and 2015.
gr2.jpg
PMC4950584_01_gr2.jpg
f0010
Despite this, the vascular dilatation found in the initial bone marrow biopsy had disappeared in the two following biopsies (Fig. 2).